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Objective: To understand how handling of missing data inﬂuences the statistical power and bias of
treatment effects in randomised controlled trials of painful knee osteoarthritis (OA).
Methods:We simulated trials with missing data (withdrawals) due to lack-of-efﬁcacy. Outcome measures
were response/non-response according to the Outcome Measures in RheumatologyeOsteoarthritis
Research Society International (OMERACTeOARSI) set of responder criteria, Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function from the WOMAC
questionnaire, and patient global assessment. We used ﬁve methods for managing missing data: ignoring
the missing data, last and baseline observation carried forward (LOCF and BOCF), and multiple impu-
tation with two different strategies. The treatment effect was then analysed by appropriate univariate
and longitudinal statistical methods, and power, bias and mean squared error (MSE) was assessed by
comparing the estimated treatment effect in the trials with missing data with the estimated treatment
effect on the trials without missing data.
Results: The best imputation method in terms of high power and low bias/MSE was our implementation
of regression multiple imputation. The most conservative method was the data augmentation Markov
chain Monte Carlo (MCMC) multiple imputation. The LOCF, BOCF and the complete-case methods were
not particularly conservative and gave relatively low power and high bias. The analysis on the WOMAC
pain scale gave less bias and higher power than the OMERACTeOARSI responder outcome measure.
Conclusions: Multiple imputation of missing data may be used to decrease bias/MSE and increase power
in OA trials. These results can guide investigators in the choice of outcome measures and especially how
missing data can be handled.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis and is
widely recognised as a major cause of chronic disability in the
population1. Thus, the interest in developing new or improved
treatments for OA is high, and this leads to a large number of OA
clinical trials. One of several problems in OA clinical trials (as for
most clinical trials) is the frequent occurrence of missing data. The
main reasons for missing data are usually lack-of-efﬁcacy, adverse
events or loss of follow-up. Missing data are a major challenge in
the analysis of the data and interpretation of the results, and is
inﬂuencing how data are analysed according to the intention-to-: I.C. Olsen, Diakonhjemmet
rway. Tel: 47-41-45-95-97;
o (I.C. Olsen).
s Research Society International. Ptreat (ITT) principle2. If missing data are treated inadequately, the
statistical power of detecting treatment effects may be reduced, the
variability might be underestimated and bias may affect the esti-
mation of the treatment effect, the comparability of the treatment
groups and the generalizability of the results3,4.
The problem of missing data is acknowledged in the liter-
ature2,4e8. It is generally accepted that no technique is generally
applicable, and reasons for missing data, properties of the outcome
measures, and the models used for analysing the end-points
require different solutions3. In general there are three much used
approaches to address missing data: (1) Approaches based on
completely recorded units discard subjects with missing outcomes
might be satisfactory with small amount of missing data, but may
lead to serious biases. (2) Model based approaches try to account
for missing data within the model, while (3) imputation based
approaches imputemore or less sensible values where the outcome
measures are missing. The purpose of imputing data is to create
a complete data set without missing data, to enable the use ofublished by Elsevier Ltd. All rights reserved.
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are imputed is important to the result. None of these approaches
solve the problem between the ITT principle and missing data, but
some methods might be better suited than others.
By simulating clinical trials with computer intensive procedures,
it is possible to compare different methods of handling missing
data9,10. By this approach, trial outcomes are generated by statis-
tical simulationmodels similar to the outcomes wewould expect to
see in real trials. Observations are then taken out according to some
pre-speciﬁed random rule, which mimics how missing data are
generated in clinical trials. By comparing analysis of simulated trial
data set with and without missing data, it is possible to assess how
the missing data inﬂuence the results.
The aim of this study was to evaluate how the management
of missing data in simulated trials did impact the estimates of
outcome and power of the proportion of responders according to
the OMERACTeOARSI set of responder criteria11. We also wanted to
explore the gains and losses of using a set of responder criteria
compared to the separate components of set, especially with
respect to missing data. We performed a simulation study in orderFig. 1. Overview of theto control all elements of an OA trial, from the design to the
missing-data mechanism. The framework was based on previous
simulation studies10.
Methods
An overview of the method used in this study is displayed in
Fig. 1.
Variables
The effect of OA treatment has traditionally been evaluated by
assessment of pain, physical function and patient’s global assess-
ment (PGA)11 A much used instrument for assessing pain and
physical function is theWestern Ontario andMcMaster Universities
Osteoarthritis Index (WOMAC) questionnaire12. We used the nor-
malised Likert version of this questionnaire (nWOMAC LK 3.1),
which scores the impact of OA on the subscales pain and physical
function on a 0e100 scale. In addition, we included a visual-
analogue (0e100) scale (VAS) for the assessment of PGA.methodology used.
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a composite outcome variable. In a joint effort, the Osteoarthritis
Research Society International (OARSI) and the Outcome Measures
in Rheumatology (OMERACT) group united for an initiative for
the harmonisation and standardisation of outcome measures
for analysis and reporting results from OA clinical trials13. The
OMERACTeOARSI initiative resulted in a set of responder criteria
for use in OA clinical trials, incorporating assessments of pain,
physical function and PGA to identify responding patients14. The
use of response to treatment as an outcome measure has several
advantages, including greater face validity, medical interpretability
and avoidance of multiple tests11.
The simulated trials
We simulated data from a model for typical outcome measures
found in OA trials. The simulated data represent a general,
unspeciﬁed two-armed randomised controlled trial (RCT) with
a control group and an experimental group with ﬁve repeated
assessments (baseline and 4, 8, 16 and 24 weeks after random-
isation). The standard deviations, withdrawal rates and time of
assessments (but not the number of arms) used in the simulations
were inspired by a large trial on the effect of glucosamine and
chondroitin sulfate compared to placebo and celecoxib in the
treatment of OA [the Glucosamine/chondroitin Arthritis Interven-
tional Trial (GAIT)]15. This trial included patients of at least 40 years
of age with clinical and radiographic evidence of OA and mild to
severe baseline pain of the knee (25e80 on the normalised
WOMAC subscale score for pain). The outcome measures were
among others OMERACTeOARSI responders, WOMAC pain and
physical function, and PGA VAS.
In order to identify OMERACTeOARSI responders, we simulated
WOMAC pain and physical function together with the PGA for each
patient at each assessment both under the null hypothesis (no
difference between the treatment groups) and under an alternative
hypothesis. The treatment differences after 24 weeks under the
alternative hypothesis were set to 9.3 and 9.7 (normalised units) for
the WOMAC dimensions pain and physical function [in accordance
with the Minimal Perceptible Clinical Improvement (MPCI)16] and
10 for the PGA VAS. Figure 2 shows the treatment difference
development by time. The standard deviations were generally set
to 22.0 (pain), 21.0 (physical function) and 27.0 (PGA). We corre-
lated the outcomes within each patient both between the indi-
vidual scores (pain, physical function and PGA) and between the
repeated assessments.
An absolute increase in the response rate of 15%, as compared
with the rate in the placebo group, was in GAIT considered to0 
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Fig. 2. WOMAC subscale scores for pain and physical function, and PGA for experi-
mental and control group in the simulation model under the alternative hypothesis.indicate a clinically meaningful treatment effect. Adopting this
ﬁgure, we calculated that a sample size of 340 patients (170 in each
group) was needed by the chi-square test to reach a power of 80%.
We simulated altogether 2000 trials with 340 patients in each:
1000 trials under the null hypothesis (no difference between the
treatment groups) and 1000 trials under the alternative hypothesis
based on the GAIT results and the MPCI (Fig. 1).
Generation of missing data
Having simulated theWOMAC pain and physical function values
together with the PGA score (forming the complete trial data set),
patient’s data were deleted according to a predeﬁned random
procedure to establish trial data sets with missing data. We deleted
data such that after the ﬁrst deleted observation all subsequent
observations were also deleted (a monotone missing pattern), thus
simulating a trial where the only source of missing data was due to
withdrawal of patients. We aimed at a withdrawal rate of 20e40%,
which must be expected in trials of 24-week duration.
We implemented two random procedures for deletion of data,
denoted as missing data scenario A and B. We wanted to make the
withdrawal probability dependent on the outcome, thus making
the data missing not at random (MNAR)7. The ﬁrst procedure for
withdrawing patients (missing data scenario A) was set to be
dependent on the mean change of the pain, physical function and
PGA assessment between two visits. The probability of withdrawal
was set to 5% if the patient had improved, 12.5% if the patient
deteriorated with less than 10 points and 30% if the deterioration
was more than 10 points. This mechanismwas expected to result in
more withdrawals in the placebo group under the alternative
hypothesis because the active treatment would protect against
deterioration in pain, physical function and PGA. The withdrawal
rate under the null hypothesis was expected to be the same for the
two treatment groups.
The second missing data procedure (missing data scenario B)
was implemented such that patients with active treatment and lack
of effect had a higher probability of withdrawing, mimicking
a process where unwanted adverse events related to the active
treatment would be inducing patients to withdraw in the case of
lack-of-efﬁcacy. For the second procedure the withdrawal proba-
bility was set to 5%, 15% and 35% in the experimental group and 5%,
10% and 25% in the control group. It was expected that the differ-
ence in withdrawal probability would level out the effect of
adherence to active treatment, and that the withdrawal rate would
be equal in the two treatment groups under the alternative
hypothesis. Under the null hypothesis, the withdrawal rate in the
active group was expected to be higher than in the placebo group.
Statistical analyses methods
As described earlier, we used four outcomemeasures in the data
sets we produced: The OMERACTeOARSI response (dichotome);
WOMAC pain and physical function (continuous); and PGA on the
VAS (continuous). The impact of missing data on the results relies
on the statistical methods used for analysing the outcome, and we
wanted to deploy several methods in order to identify differences
between them. We used two different strategies for statistical
analyses, univariate and longitudinal. For the univariate analyses
we used the last visit (after 24 weeks) observation only, while for
the longitudinal analysis we used the observations from all visits. In
the univariate analysis the treatment difference was assessed using
the chi-square test for the dichotome response outcome and the
Analysis of Covariance (ANCOVA) model (adjusting for baseline) for
the continuous outcomes. In the longitudinal analysis we used
repeated logistic regression (by generalised estimating equations
Table I
Mean withdrawal rate in simulated trials by hypothesis, scenario and treatment
group
Hypothesis Missing data
procedure
Experimental
group (%)
Control
group (%)
Total (%)
Null Scenario A 33.6 33.4 33.5
Scenario B 30.6 36.3 33.5
Alternative Scenario A 28.7 33.6 31.1
Scenario B 30.5 30.5 30.5
Scenario A: Withdrawal probability dependent only on outcome (higher if deteri-
orating).
Scenario B: Withdrawal probability dependent both on outcome and treatment
(higher if deteriorating and in the experimental group).
Null hypothesis: No difference between the groups.
Alternative hypothesis: Treatment group differences as indicated by Fig. 2.
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for repeated measures (MMRM)7 for the continuous outcomes.
These methods represent much used methods for dichotome
and continuous measures in RCTs. The univariate analyses corre-
spond to the methods used by Clegg et al.15, while longitudinal
methods are advocated to increase precision and accommodate
missing data. With respect to missing data it has been shown that
likelihood based methods (such as mixed models and generalized
linear mixed models) will provide unbiased estimates if the data
are missing at random (MAR)7. The MAR assumption is fulﬁlled if
we can assume that the data are missing independent of what we
would have observed if the data were not missing, but might be
dependent on what we have observed (outcome measures and
covariates). Note that this result does not apply to methods based
on GEE, which generally requires data to be missing completely at
random (MCAR) to yield unbiased estimates. We can assumeMCAR
if the data are missing independent of both observed and unob-
served measures, which is a stronger assumption than MAR.
Methods for handling missing data
Numerous methods exist for handling missing data in statistical
analyses7. In this study we applied ﬁve methods for handling
missing data: the case-complete (all available data) method, the
last and baseline observation carried forward (LOCF and BOCF)
methods and two different approaches of multiple imputation (MI).
The case-complete method ignores the missing data and the
analyses are based only on observed data. For the univariate anal-
ysis this means that missing observations were omitted, while for
the longitudinal analysis all available observations were included in
the analysis. The LOCF and BOCF methods are single imputation
methods where the last known observation (LOCF) or the baseline
observation (BOCF) is carried forward for all withdrawn subjects.
The MI method replaces each missing value of an incomplete data
set with a set of plausible values that represent the uncertainty in
the correct value to impute7,10,18. We used two different methods
for the imputation: (1) The data augmentationMarkov chainMonte
Carlo (daMCMC) replacement method19 is often used as it only
takes into account the correlation between the observations and
does not model the missing data further. It is also applicable for
intermediate missing values. By the way we implemented this
method we did not take possible effects of treatment into consid-
eration. This is a very conservative approach, as it assumes no
treatment effect for the imputed values in the experimental treat-
ment group. (2) The regression method ﬁts a regression model to
the data and uses this ﬁtted model to impute missing values. The
regression method requires monotone missing data, meaning that
once a subject has a missing value, the remaining values are also
missing for this subject7. This requirement was met in our simu-
lated trials. We implemented the regression MI method with
treatment as an exploratory factor in the regression model. This
approach is less conservative than our implementation of the
daMCMC MI method.
After the imputation, each simulated trial was analysed by the
corresponding statistical models (univariate and longitudinal), and
results were combined in a single analysis yielding point estimates
and standard errors. We used 10 imputations for each missing
observation.
Measuring impact of missing data
We effectively simulated 4000 trials (2000 simulated trial data
sets with two different procedures for missing data) with 340
patients in each. For each simulated trial we applied the different
methods for handling missing data and analysed them with thedifferent statistical methods. The results from the analyses of the
trial data sets with missing data were then compared with the
original (nomissing values) data. In this waywewere able to assess
the impact that the different approaches for handling missing data.
The different methods for handling missing data were assessed
by (1) the ability towrongfully reject the null hypothesis (the Type I
error), (2) the power to discover true differences between the
treatments, (3) the bias of the estimated treatment effect compared
to the treatment effect of the original (no missing values) data and
(4) the mean squared error (MSE). These four assessments were
regarded as the outcome measures of our study.
We estimated the probability of wrongfully rejecting the null
hypothesis (Type I error) by analysing the simulated trials under
the null hypothesis. The probability of a Type I error was calculated
as the proportion of trials with P-values less than 0.05. Analysing
the simulated alternative-hypothesis trials and calculating the
proportion of trials that rejected the null-hypotheses estimated the
power. We calculated the bias of the estimated treatment effect by
the absolute and relative difference between the average estimated
treatment effect of the trials with and without missing data. The
MSE was calculated as the sum of the estimated variance of the
treatment effect and the squared absolute bias.
The simulations were performed using R 2.8.1 (R Foundation for
Statistical Computing, Vienna, Austria), and the handling of missing
data and data analysis was performed using SAS 9.2 (SAS Institute,
Cary, USA).
Results
Rate of missing data
The withdrawal rates according to hypothesis and missing data
procedures are presented in Table I. As expected, the withdrawal
rate under the null hypothesis is almost equal for missing data
scenario A, while there is an increased withdrawal rate in the
experimental group for scenario B. Under the alternative hypoth-
esis there is a higher withdrawal rate in the control group for
scenario A, while thewithdrawal rate is almost equal for scenario B.
Analysis of the OMERACTeOARSI responders
For the univariate analyses, the probability of Type I error was
below 5% for all approaches under bothmissing data scenario A and
B, except for the case-complete approach under scenario B. For the
longitudinal analyses, the probability of Type I error was above 5%
for the case-complete and LOCF approach for both scenarios in
addition to the BOCF approach for scenario B. The MI daMCMC
approach generally had the lowest probability of Type I error
(Table II).
Table II
Type I error and power after simulation with different management strategies for missing data for responders applying OMERACTeOARSI criteria
Missing data
procedure
Data
analysis
Management of
missing data
Null hypothesis Alternative hypothesis
Probability of
Type I error (%)
Power (%) Treatment effect:
relative bias*
Treatment effect:
absolute biasy
MSE
None Chi-square Complete data setz 4.3 90.2 0 0 25.1
GEE Complete data setz 5.5 91.6 0 0 25.1
Scenario A Chi-square Case-complete 4.5 67.1 14.5 2.5 39.6
LOCF 4.5 74.6 15.7 2.7 34.9
BOCF 3.7 69.9 18.9 3.3 40.9
MI daMCMC 1.1 54.3 32.4 5.6 49.5
MI regression 3.4 79.4 9.3 1.6 28.1
GEE All available data 5.5 71.5 5.8 1.1 42.1
LOCF 5.4 77.0 21.7 4.1 41.4
BOCF 4.9 72.9 26.9 5.0 52.5
MI daMCMC 0.9 53.5 26.4 4.9 47.0
MI regression 3.2 78.8 3.0 0.6 29.2
Scenario B Chi-square Case-complete 6.0 80.4 1.8 0.3 34.1
LOCF 4.2 68.3 22.5 3.9 42.6
BOCF 4.9 56.1 29.4 5.0 55.0
MI daMCMC 1.0 67.7 24.7 4.3 37.2
MI regression 4.7 87.8 0.4 0.1 26.5
GEE All available data 7.8 83.9 7.1 1.3 41.1
LOCF 5.4 73.2 27.8 5.2 52.9
BOCF 6.1 59.3 36.1 6.8 72.6
MI daMCMC 0.9 65.6 18.8 3.5 35.5
MI regression 4.4 87.0 5.7 1.1 30.2
Scenario A: Missing data as function of lack-of-efﬁcacy with 28.7% drop-out in the experimental group and 33.6% drop-out in the control group.
Scenario B: Missing data as function of lack-of-efﬁcacy with 30.5% drop-out in both the experimental and the control treatment group.
* Expressed as percentage.
y Expressed as OMERACTeOARSI responder rate in percent.
z Original data sets with no missing data.
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and highest for the MI regression approach. The lowest bias and
MSE was attained using MI regression approach whatever the
analysis, while the highest was attained using the MI daMCMC
approach. Note that there were two longitudinal analyses with
a positive bias under scenario B (case-complete and MI regression)
(Table II).
Analysis of the continuous variables
The results from the WOMAC pain, physical function and PGA
were similar and only results from the WOMAC pain scale are
presented (Table III). Generally the power was higher and the
treatment effect less biased compared to the results for the
OMERACTeOARSI responders. The best results (lowest bias/MSE
and largest power) were found for the MI regression method and
for repeated analysis of the case-complete method. The Type I error
rate was generally too high for these methods, especially for the
case-complete method. The lowest probability of making a Type I
error was found for the MI daMCMC method (Table III).
Discussion
This simulation study examined various approaches to manage
missing data in RCTs of OA treatments with both dichotomized and
continuous outcome measures. The overall best method with
highest power and lowest bias for imputing missing data was the
MI method with a regression model where the treatment was
included as an explanatory factor. The lowest probability of a Type I
error was achieved by MI using the daMCMC approach with no
treatment factor. This approach may therefore be regarded as the
most conservative.
There are other studies assessing the impact of missing data in
rheumatology. A simulation study onmissing data methods in RCTs
of rheumatoid arthritis with radiographic outcomes showed thatMI was superior to other methods in terms of bias and power2. For
osteoporosis, a simulation study evaluated different handling
strategies for missing data (not including MI) without concluding
with a preferred method8. For OA, the inﬂuence of several impu-
tation techniques (including LOCF and MI) on the sample size
estimation has been shown in a study focussing on a radiographic
outcome5. To our knowledge, the current simulation study is the
ﬁrst to assess the impact of missing data on outcomes in a clinical
trial in OA.
The MI method generally consists of two distinct parts. The ﬁrst
part is the imputation; the second part is the analysis of the
imputed data sets where the uncertainty introduced in the impu-
tation part is included in the estimates. These two parts can be
handled separately, even using different models. We did this in our
daMCMC MI method since we modelled the data without a treat-
ment term in the imputation part, while we did the analysis in the
second step with a treatment term. This is called uncongenial
modelling of the imputation20, in contrast to congenial modelling
where the imputation model and the analysis model are consistent
(as we did in the regression method). Effectively, modelling
without a treatment term means that we impute values assuming
that there are no differences between the groups. This clearly
introduces a bias in our estimates, but the bias is conservative.
Using MI with a model without a treatment term offers a very good
method for sensitivity analysis since it is transparent, it is conser-
vative and it takes the uncertainty of the imputations into consid-
eration (as opposed to single imputation methods).
The analysis of the WOMAC pain outcome measure generally
gave less bias and higher power than the OMERACTeOARSI
responder outcome measure, but was slightly more prone to Type
I errors. This also applied to theWOMAC physical function and PGA
measures (data not shown). This ﬁnding can be relevant when
selecting a primary outcome measure for clinical trials. Generally it
is advised that efﬁcacy should not be assessed on only one domain
(e.g., pain). The adopted European view is that “Studies should be
Table III
Type I error and power after simulation with different management strategies for missing data for WOMAC pain variable
Missing data
procedure
Data
analysis
Management of
missing data
Null hypothesis Alternative hypothesis
Probability of
Type I error (%)
Power
(%)
Treatment effect:
relative bias*
Treatment effect:
absolute biasy
MSE
None ANCOVA Complete data setz 5.2 96.0 0.3 0 6.5
MMRM Complete data setz 4.8 98.4 0.4 0 5.3
Scenario A ANCOVA Case-complete 4.9 82.6 8.5 0.8 10.0
LOCF 4.9 86.7 16.0 1.6 9.3
BOCF 6.8 80.7 26.2 2.5 12.9
MI daMCMC 1.2 68.4 29.4 2.9 13.7
MI regression 4.7 84.3 6.2 0.6 8.9
MMRM Case-complete 5.2 92.5 5.3 0.5 7.4
LOCF 5.5 93.6 15.9 1.5 8.0
BOCF 5.9 90.5 26.2 2.5 11.4
MI daMCMC 0.6 77.3 29.4 2.9 12.4
MI regression 4.9 90.3 6.1 0.6 7.7
Scenario B ANCOVA Case-complete 7.1 89.2 0.1 0 9.1
LOCF 5.8 84.9 18.9 1.8 10.2
BOCF 5.1 78.5 28.7 2.8 14.9
MI daMCMC 1.5 77.7 23.0 2.2 10.4
MI regression 5.8 90.1 1.4 0.1 8.5
MMRM Case-complete 6.2 95.4 1.5 0.1 7.1
LOCF 4.8 92.7 18.8 1.8 8.9
BOCF 4.1 84.6 28.6 2.8 13.4
MI daMCMC 1.3 86.2 23.0 2.2 9.2
MI regression 5.5 94.0 1.5 0.1 7.2
ANCOVA ¼ Analysis of Covariance with baseline value as covariate.
Scenario A: Missing data as function of lack-of-efﬁcacy with 28.7% drop-out in the experimental group and 33.6% drop-out in the control group.
Scenario B: Missing data as function of lack-of-efﬁcacy with 30.5% drop-out in both the experimental and the control treatment group.
* Expressed as percent.
y Expressed in terms of normalised WOMAC subscale score for pain units.
z Original data sets with no missing data.
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functional disability”1. This introduces multiplicity in the analyses
that needs to be addressed.
The impact of missing data in RCTs is difﬁcult to assess and is
related to the question of what would have been observed if no
patient had withdrawn from the trial. If we can assume that the
data are MAR, any estimators based on the maximum likelihood
principle will provide unbiased estimates7. In our study, both the
MMRM analysis of all available data as well as MI with a treatment
term produce maximum likelihood based estimates, and are
equivalent under theMAR assumption.When the data are assumed
to be MAR, MMRM models might be preferable to MI methods
because they are easier to implement. The MAR assumption is,
however, usually not met in RCTs3. By utilising simulated data we
were able to observe how missing data, which are not MAR,
inﬂuence the analyses. We considered two situations where the
missing data were dependent on what would have been observed.
Both our procedures to delete data imitate withdrawal due to lack-
of-efﬁcacy, with a high probability of withdrawal if the condition
worsens. In scenario A the mechanism was equal for both treat-
ments, resulting in an expected higher withdrawal rate for the
control group under the alternative hypothesis. In scenario B the
mechanism was designed in disfavour of the experimental group,
resulting in an expected equal withdrawal rate between the groups
under the alternative hypothesis. Interestingly, the missing data
mostly resulted in an underestimation of the treatment effect. The
underestimation is quite understandable for the MI daMCMC and
BOCF methods since they effectively impute values with no
difference between the treatment groups. For the other methods
the situation is subtler, but the overestimation of the treatment
effect for the repeated analysis of the MI regression data is not
reassuring. Results from scenario B indicate that the use of repeated
logistic regression could be less suitable for the OMERACTeOARSI
responders, especially since the overestimation is much less
pronounced in the analysis of WOMAC pain.The most important property of any method for handling
missing data is to avoid a wrongfully rejection of the null hypoth-
esis (Type I error). In our study, most methods gave an adequate
control of the Type I error with the exception of the analysis of case-
complete data, which resulted in a too high probability of Type I
error (especially for scenario B). Interestingly, the BOCF method
was not particularly conservative with respect to Type I error,
although it underestimated the treatment effect most. When the
Type I error is controlled, the bias, power and MSE are equally
important and linked such that a biased estimator induces low
power and high MSE.
An important understanding resulting from this study is that the
handling of missing data inﬂuences the results, and that there is no
uniformly best method (although some are better than others). This
points to two important implications for the analysis of RCTs: (1) In
order to avoid selective reporting of results according to handling of
missing data, the method used for the primary endpoint should be
pre-speciﬁed in the protocol. (2) To show the impact of missing
data on the results, robustness analyses with different missing data
approaches should be presented.
Simulation studies have in general numerous limitations. In the
current study, generation of missing data covered only some of the
many reasons for missing data assumed to apply to OA RCTs.
Different reasons might result in other effects than described here.
Secondly, we have not considered other more case-speciﬁc
methods for the handling of missing data. Each trial has speciﬁc
bias for missing data, and there might be tailored methods avail-
able. Furthermore, the underlying trial that we used might not be
suitable for other situations.
Missing data may lead to invalid conclusions if not treated
appropriately. In this study we have shown that the preferred
method is the MI technique with a treatment term. The most
conservative method is MI without a treatment term, and this latter
method would be particularly relevant to assess the robustness of
results when there are large differences in withdrawal rates
I.C. Olsen et al. / Osteoarthritis and Cartilage 20 (2012) 822e828828between the treatment arms. The LOCF, BOCF and the complete-
case methods were not particularly conservative and gave rela-
tively low power and high bias. The results from this study can
support investigators in their choice of methods to handle missing
data in OA clinical trials.
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